Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
NEW YORK, May 02, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSE:IMUC) between May 1, 2012 and December 11, 2013. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/immunocellular-therapeutics-ltd
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which had engaged in stock promotion schemes.
If you suffered a loss in ImmunoCellular Therapeutics you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
